Detalles de la búsqueda
1.
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe.
Ann Oncol
; 34(10): 934-945, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37406812
2.
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Ann Oncol
; 34(10): 920-933, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37704166
3.
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Ann Oncol
; 34(5): 468-476, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36863484
4.
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Ann Oncol
; 34(4): 389-396, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36709039
5.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Ann Oncol
; 33(4): 434-444, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35066105
6.
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors.
Ann Oncol
; 33(10): 1041-1051, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35850444
7.
Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Ann Oncol
; 32(6): 698-709, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33737119
8.
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Ann Oncol
; 32(5): 620-630, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33639216
9.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Ann Oncol
; 32(11): 1381-1390, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416362
10.
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Ann Oncol
; 32(11): 1391-1399, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34400292
11.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Ann Oncol
; 30(8): 1321-1328, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31125062
12.
Are liquid biopsies a surrogate for tissue EGFR testing?
Ann Oncol
; 29(suppl_1): i38-i46, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462257
13.
A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Ann Oncol
; 28(7): 1523-1531, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28633480
14.
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Ann Oncol
; 28(4): 784-790, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28104619
15.
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Ann Oncol
; 28(11): 2715-2724, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28945865
16.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Ann Oncol
; 28(5): 1078-1083, 2017 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327934
17.
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Ann Oncol
; 33(12): 1328-1331, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36122799
18.
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Ann Oncol
; 27(2): 281-6, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26598547
19.
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
Ann Oncol
; 32(7): 936-937, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33865965
20.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ.
Ann Oncol
; 32(7): 839-853, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33864941